This website uses cookies to enhance user experience and to analyze performance and traffic on our website. We may also share information about your use of our site with analytics partners. Read about cookies in our Cookie Policy. By clicking “Accept”, you are indicating your consent to our use of cookies and policies.

ANGITIA - INNOVATION FOR PATIENTS
Media
News
2025-03-18
Angitia Biopharmaceuticals Presents Data from Phase 1/2 Study of AGA111 at 2025 AAOS Annual Meeting
AGA111 treatment resulted in high spinal fusion success rate and improved functional outcomes
More……
2025-01-08
Angitia Biopharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
More……
2024-12-11
Angitia Biopharmaceuticals Announces $120 Million Series C Financing
Financing led by Bain Capital Life Sciences with significant participation from existing and new investors
More……
2024-11-04
Angitia Biopharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of AGA2118 for the Treatment of Osteoporosis
Phase 2 study to be conducted in the US and EU
More……
2024-09-30
Angitia Biopharmaceuticals Presents First-in-Human Data on AGA2118 for Osteoporosis at ASBMR 2024
Angitia Biopharmaceuticals Presents First-in-Human Data on AGA2118 for Osteoporosis at ASBMR 2024
More……
2024-09-17
Angitia Biopharmaceuticals to Present Data on AGA2118 for Osteoporosis at ASBMR 2024
Abstracts selected for 2 oral presentations and 2 poster presentations, including clinical and preclinical data sets
More……
2024-05-16
Angitia Biopharmaceuticals Announces Topline Results from First in Human Study of AGA2118
WOODLAND HILLS, California, USA, May 16, 2024 – Angitia Biopharmaceuticals, a global, clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced positive top-line results from its first in human (FIH) study of AGA2118. The study, entitled “A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability, Absolute Bioavailability, Pharmacokinetics, and Pharmacodynamics of AGA2118 in Men and Postmenopausal Women”, demonstrates an excellent safety and tolerability profile, as well as preliminary efficacy in increasing bone mineral density (BMD) after single and multiple dose administrations.
More……
2024-04-09
Angitia Biopharmaceuticals Announces the Appointment of Michael H. Arenberg as Chief Financial Officer
WOODLAND HILLS, California, USA, April 8, 2024 – Angitia Biopharmaceuticals, a global, clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced the appointment of Michael H. Arenberg, J.D., M.B.A., as Chief Financial Officer (CFO), effective April 8th, 2024.
More……
2024-02-28
Angitia Biopharmaceuticals Completes US$40M Second Close of Series B Extension Financing
Angitia Biopharmaceuticals, a global clinical-stage biotechnology company announces the completion of an additional US$40M Series B Extension financing in January 2024 led by YueKai Health, a market-oriented VC funded by GZHT Technology Holding and managed by Yuekai Capital. Combined with the US$46M Series B Extension financing completed in October 2023, Angitia has now raised US$86M in the Series B Extension.
More……
2023-12-08
Angitia Biopharmaceuticals Announces the First Subject Dosed in a Phase III Registrational Trial of AGA111, a Drug Candidate for Enhancing Spinal Fusion
Guangzhou, China and Woodland Hills, California, USA – December 8th, 2023, Angitia Biopharmaceuticals, a global clinical-stage biotechnology company, announced today that the first subject has been successfully dosed in a Phase III registrational clinical trial of AGA111.
More……